Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review. Issue 5 (June 2021)

• Record Type: Journal Article
• Authors: Batra, Anupam; Marchioni, Michele; Hashmi, Ardeshir Z.; Lonergan, Peter E.; Morgans, Alicia K.; Nead, Kevin T.; Nguyen, Paul L.; Winquist, Eric; Chin, Joseph L.
• Is Part Of: Journal of geriatric oncology. Volume 12:Issue 5(2021)
• Page Start: 687
• Page End: 695
• Publication Date: 2021-06
• Subjects: Depression -- Cognition -- Androgen receptor axis-targeted drugs -- Older men -- Prostate cancer; Geriatric oncology -- Periodicals; Neoplasms -- Periodicals; Aged -- Periodicals; Geriatric oncology; Electronic journals; Periodicals; 618.976994005
• DOI: 10.1016/j.jgo.2020.11.002
• Languages: English
• ISSNs: 1879-4068

Abstract

Abstract: Context: Novel androgen receptor axis-targeting drugs (ARATs) have been shown to improve outcomes in men with prostate cancer. Central nervous system androgen blockade may be harmful for older adults who may be at increased risk of adverse cognitive and psychologic effects. Objective: To systematically evaluate the effect of ARATs on cognition and depression in men with metastatic prostate cancer. Evidence acquisition: We searched PubMed and EMBASE for articles published in English between September 2012 and September 2019 reporting cognition and depression outcomes in men receiving ARATs for metastatic prostate cancer using validated psychometric tools. The level of evidence and risk of bias were assessed using the GRADE approach for randomized clinical trials and observational studies. Results: 15 reports studying 8954 men with metastatic castration-sensitive and -resistant, or non-metastatic castration-resistant prostate cancer were identified. Data were available for abiraterone, enzalutamide and apalutamide but not darolutamide. The mean (and 95% confidence interval) and median (and min-max) of the absolute scores and changes from baseline were included, when available. There was heterogeneity in the psychometric tools used which obviated statistical pooling of results. Very limited data assessing cognition suggested that abiraterone was associated with improved cognitive functioning or perhaps less cognitive harm versus enzalutamide. Fourteen reports assessed emotional wellbeing. ARATs reduced depressive symptoms when compared to prednisone alone or placebo but not compared to bicalutamide. Abiraterone may improve short-term emotional functioning relative to enzalutamide. The quality of evidence was low when examining ARAT effect on cognitive function and moderate when examining ARAT effect on depression. Conclusions: Depression was assessed more frequently than cognition in men receiving ARATs. Self-reported depression measures favored abiraterone over enzalutamide and both abiraterone and enzalutamide over placebo. Data evaluating apalutamide and darolutamide are lacking. Further studies of ARATs using validated clinician-based psycho-cognition tools along with self-reported measures in men with metastatic prostate cancer are needed.